84 reports of this reaction
1.2% of all ATAZANAVIR SULFATE reports
#17 most reported adverse reaction
PREMATURE DELIVERY is the #17 most commonly reported adverse reaction for ATAZANAVIR SULFATE, manufactured by Aurobindo Pharma Limited. There are 84 FDA adverse event reports linking ATAZANAVIR SULFATE to PREMATURE DELIVERY. This represents approximately 1.2% of all 6,992 adverse event reports for this drug.
Patients taking ATAZANAVIR SULFATE who experience premature delivery should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PREMATURE DELIVERY is a less commonly reported adverse event for ATAZANAVIR SULFATE, but still significant enough to appear in the safety profile.
In addition to premature delivery, the following adverse reactions have been reported for ATAZANAVIR SULFATE:
The following drugs have also been linked to premature delivery in FDA adverse event reports:
PREMATURE DELIVERY has been reported as an adverse event in 84 FDA reports for ATAZANAVIR SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PREMATURE DELIVERY accounts for approximately 1.2% of all adverse event reports for ATAZANAVIR SULFATE, making it a notable side effect.
If you experience premature delivery while taking ATAZANAVIR SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.